Zusammenfassung
Idiopathische Myositiden sind erworbene Muskelerkrankungen, die teilweise auf eine immunmodulatorische Therapie ansprechen. Da auch bestimmte Muskeldystrophien und metabolische Erkrankungen entzündliche Infiltrate aufweisen können, ist die Kenntnis der diagnostischen Kriterien für den Neuropathologen von Bedeutung. Idiopathische Myositiden können generalisiert bzw. multifokal vorkommen (Dermatomyositis, Polymyositis, sporadische Einschlusskörperchenmyositis) oder fokal auftreten (z. B. proliferative Myositis, Makrophagenmyofasziitis). Diese Übersicht vermittelt diagnostische Kriterien für die Myositiden und – soweit bekannt – Daten zum pathogenetischen Mechanismus.
Abstract
Idiopathic inflammatory myopathies (IIM) are diseases that are potentially amenable to immunomodulatory therapy. The challenge for the neuropathologist consists in distinguishing these myopathies from secondary inflammatory myopathies, especially in the context of some muscular dystrophies and metabolic diseases that may also show inflammatory infiltrates. There are generalized IIMs (dermatomyositis, polymyositis, sporadic inclusion body myositis) and focal ones (e.g., proliferative myositis, macrophagic myofasciitis). This review provides diagnostic criteria for each of these and includes pathogenetic mechanisms where available.
Literatur
Amemiya K, Granger AP, Dalakas M (2000) Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123:2030–2039
Askanas V, Engel WK (2001) Inclusion body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60:1–14
Badrising UA, Maat-Schieman M, van Duinen SG et al (2000) Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55:1385–1387
Barohn RJ, Amato AA, Sahenk Z et al (1995) Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 45:1302–1304
Bronner IM, Hoogendijk JE, Veldman H et al (2008) Tubuloreticular structures in different types of myositis: implications for pathogenesis. Ultrastruct Pathol 32:123–126
Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic inclusion body myositis. Neurology 70:418–424
Emslie-Smith AM, Engel AG (1990) Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27:343–356
Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371:2201–2212
Gherardi RK, Coquet M, Cherin P et al (2001) Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124:1821–1831
Goebels N (2004) Polymyositis und Dermatomyositis. In: Spuler S, von Moers A (Hrsg) Muskelkrankheiten. Grundlagen, Diagnostik und Therapie. Schattauer, Stuttgart, S 194–206
Greenberg SA, Pinkus GS, Amato AA, Pinkus JL (2007) Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 35:17–23
Greenberg SA, Amato A (2004) Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 17:359–364
Gunawardena H, Betteridge ZE, McHugh NJ (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20:675–680
Hengstman GJ, van Engelen BG (2004) Polymyositis, invasion of non-necrotic muscle fibers, and the art of repetition. BMJ 329:1464–1467
Hoogendijk JE, Amato AA, Lecky BR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345
López de Padilla CM, Reed AM (2008) Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheumatol 20:669–674
Lundberg IE, Grundtman C (2008) Developments in the scientific and clinical understanding of inflammatory myopathies. Arthritis Res Ther 10:220 (doi:10.1186/ar2501)
Mastaglia FL (2008) What to do … When the treatment does not work: polymyositis. Pract Neurol 8:170–174
Mendell JR, Sahenk Z, Gales T, Paul L (1991) Amyloid filaments in inclusion body myositis: Novel findings provide insight into nature of filaments. Arch Neurol 48:1229–1234
Mozaffar T, Lopate G, Pestronk A (1998) Clinical correlates of granuloma in muscle. J Neurol 245:519–524
Price P, Santoso L, Mastaglia F et al (2004) Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens 64:575–580
Rosenberg AE (2008) Pseudosarcoma of soft tissue. Arch Pathol Lab Med 132:579–586
Shamim EA, Rider LG, Miller FW (2000) Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 12:482–491
Stevens AM, Sullivan KM, Nelson JL (2003) Polymositis as a manifestation of chronic graft-versus-host disease. Rheumatology 42:34–39
Tomasová Studýnková J, Charvát F, Jarošová K, Vencovský J (2007) The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 46:1174–1179
Van der Meulen MF, Bronner IM, Hoogendijk JE et al (2004) Polymyositis: an overdiagnosed entity. Neurology 61:316–321
Walker UA (2008) Imaging tools for the clinical assessment of idiopathic inflammatory myositis. Curr Opin Rheumatol 20:656–661
Interessenkonflikt
Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bornemann, A., Heitmann, S. & Lindner, A. Myositiden. Pathologe 30, 352–356 (2009). https://doi.org/10.1007/s00292-009-1167-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-009-1167-7